The Department of Health and Human Services announced the first list of Medicare Part D drugs subject to price negotiations, a tenet of the Inflation Reduction Act designed to reduce health care costs. HHS said the selected drugs accounted for $50.5 billion in total Part D gross covered prescription drug costs, or about 20%, of total Part D gross covered prescription drug costs between June 1, 2022, and May 31, 2023.

Drugmakers will need to sign agreements to join negotiations by Oct. 1, with the Center for Medicare & Medicaid Services making initial price offers in February 2024. The drugmakers will then have a month to accept or make a counteroffer. The resulting agreed-upon negotiated prices for the 10 drugs will be published by CMS by Sept. 1, 2024, with the prices taking effect Jan. 1, 2026. Additional drugs could be added to the list in future years.

Drugmakers that decline to negotiate the prices of selected drugs with CMS will be required to either pay an excise tax of up to 95% of U.S. sales or pull all its products from the Medicare and Medicaid markets.

Related News Articles

Headline
The White House May 12 released an executive order to reduce prescription drug costs by allowing consumers to make direct purchases from drug manufacturers at…
Headline
The House Energy and Commerce Committee late on May 11 released legislative text in advance of the May 13 markup on its portion of the reconciliation bill.…
Headline
The House committees with jurisdiction over Medicaid and other health care programs have announced they will begin marking up their portions of the budget…
Headline
Freshman Sens. Elissa Slotkin, D-Mich., and Ruben Gallego, D-Ariz., May 6 joined former CNN correspondent Frank Sesno at the 2025 AHA Annual Membership Meeting…
Headline
Rep. Nathaniel Moran, R-Texas, and Rep. Brad Schneider, D-Ill., both members of the House Ways and Means Committee, spoke to the AHA Annual Membership Meeting…
Headline
Rep. Mariannette Miller-Meeks, R-Iowa, participated in a fireside chat during the afternoon plenary session May 5 at the 2025 AHA Annual Membership meeting. As…